IRulya Therapeutics Quarterly Cash Flow Statement
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.88-0.06 (-0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics free cash flow
In the quarter ended Sep 30, 2026, IRulya Therapeutics generated -$9.8 million of operating cash flow and spent $71,000 on capital expenditures. That left free cash flow of -$9.9 million.
Summary generated from market data by MetaCap's automated system. Methodology
IRulya Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -27.74M | -75.49M | 35.91M | -39.46M | -13.44M | -16.05M | -15.03M | -12.46M | -5.49M | -27.73M | -11.15M | -8.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 15.00K | 41.00K | 36.00K | 39.00K | 36.00K | 35.00K | 32.00K | 16.00K | 86.00K | 44.00K | 40.00K | 304.00K |
| Stock-Based Compensation | 1.64M | 12.09M | 1.29M | 1.19M | 1.25M | 1.27M | 1.39M | 1.13M | 1.12M | 1.22M | 1.27M | 1.09M |
| Change in Working Capital | 3.23M | -66.00K | 2.97M | 2.38M | 1.23M | -1.82M | 965.00K | 1.67M | -808.00K | -1.26M | -381.00K | 1.85M |
| Operating Cash Flow | -9.84M | -18.89M | -7.63M | -10.48M | -9.93M | -11.41M | -9.60M | -7.55M | -7.26M | -8.74M | -8.35M | -6.08M |
| Capital Expenditures | -71.00K | 0 | 0 | -4.00K | -74.00K | -126.00K | -148.00K | -133.00K | -46.00K | -39.00K | -39.00K | -24.00K |
| Investing Cash Flow | -67.79M | 8.00M | 12.00M | 8.07M | -1.78M | 6.04M | 10.90M | 10.87M | 7.11M | -4.98M | 8.91M | 5.39M |
| Financing Cash Flow | -10.00K | 108.93M | 9.44M | 2.03M | 1.38M | 14.41M | 87.00K | 0 | -5.00M | 35.00K | 190.00K | 57.00K |
| Net Change in Cash | -76.16M | 97.82M | 12.35M | -643.00K | -10.37M | 9.05M | 1.56M | 3.54M | -5.21M | -13.92M | 1.06M | -880.00K |
| Free Cash Flow | -9.91M | -18.89M | -7.63M | -10.48M | -10.00M | -11.54M | -9.75M | -7.68M | -7.31M | -8.78M | -8.39M | -6.10M |
This table shows 12 quarterly periods of IRulya Therapeutics's cash flow statement, from Q3 2026 back to Q4 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a cash flow statement?